Cargando…
First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
Thirty-one consecutive patients with advanced epithelial ovarian cancer entered a phase II study with cisplatin and etoposide combination chemotherapy. None of them had received prior chemotherapy or radiotherapy. Most patients had advanced (88%) or far advanced (61%) disease. All 31 patients are ev...
Autores principales: | Athanassiou, A. E., Bafaloukos, D., Pectasides, D., Dimitriadis, M., Varthalitis, I., Barbounis, V. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247295/ https://www.ncbi.nlm.nih.gov/pubmed/2803952 |
Ejemplares similares
-
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989) -
Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial
por: Shi, Tingyan, et al.
Publicado: (2018) -
First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998) -
Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002) -
Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer
por: Watanabe, R, et al.
Publicado: (2003)